Company intelligence / Profile preview

Shandong Gujin Traditional Chinese Medicine Technology Co., Ltd.

Shandong Province, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

The company has two drugs that have received IND Approval: Chaiguijiegan Granules for acute upper respiratory infection and Tengshen Granules for hypertension.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Herbal medicineTraditional Chinese Medicine formulations
Industry: Biotech

Drug pipeline

1 asset

LBRAD

Commercial

Indications: Depression, Anxiety, Sleep disorders, Post-COVID-19 depression

Partnerships

Shandong University of Traditional Chinese MedicineAffiliated Hospital of Shandong University of TCM

Beyond the preview

Go deeper on Shandong Gujin Traditional Chinese Medicine Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shandong Gujin Traditional Chinese Medicine Technology Co., Ltd..

Explore the full profile